For years, cannabinoids, the chemicals found in the cannabis plant, have been widely known for their therapeutic and medicinal abilities. Scientists have identified at least 113 different chemicals in the plant — with tetrahydrocannabinol (THC) and cannabidiol (CBD) — known for treating epilepsy, multiple sclerosis, chronic pain, chemotherapy-induced nausea, HIV complications, and a variety of other chronic disease states. Studies have shown that cannabinoids may be beneficial in fighting cancer, while chemicals found in the cannabis plant are also under investigation as possible treatments for immune system diseases, including HIV/AIDS, multiple sclerosis (MS), and lupus. Considering the potential benefits that can be derived from cannabinoids, experts have called for more research to harness its full potential. However, there certainly have been roadblocks to this. Apart from the lack of available funds and pharmaceutical-grade cannabinoids to support high-quality research, another barrier is the U.S. Drug Enforcement Administration’s (DEA) decision to categorize marijuana as a Schedule I drug — the same as heroin, ecstasy, and LSD. Due to this classification by the DEA, researchers and institutions need a special license to study, develop, and harness the possibly enormous untapped benefits of cannabinoids. To help advance research and also help tap into the full benefits of cannabinoids, Clever Leaves (NASDAQ: CLVR), a multinational cannabis company, has launched Project Change Lives to make that dream a reality. The company, which emphasizes ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabis business, is hoping to leverage the Project Change Lives initiative to cause a paradigm shift and advance domestic research into cannabinoids.

420 Intel – Marijuana Industry News, 09/22/2021 20:00:00

Open article: